Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Prothena Corporation plc (PRTA) Guidance & Earnings Results

On 2026-08-06 Prothena Corporation plc issued guidance: "Cash guidance updated to ~$259M…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

PRTAProthena Corporation plcFollow PRTA — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
421.0M
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
29 Oct, in 5 days

What management guided

each earnings 8-K · figures checked against the filing text
ReleaseDirectionWhat they said
6 Aug 26—Cash guidance updated to ~$259M year-end · full year
7 May 26RaisedFY2026 net cash used guidance improved to $18-23M from $50-55M · full year
19 Feb 26ReaffirmedFY2026 net cash used in operating and investing activities $50-55M; year-end cash ~$255M. · full year

Prothena Corporation plc — questions

What guidance did Prothena Corporation plc give?
On 2026-08-06: "Cash guidance updated to ~$259M year-end"
When does Prothena Corporation plc report earnings?
Prothena Corporation plc's next earnings report is expected on 2026-10-29.

Every figure on this page comes from Prothena Corporation plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.